POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER).
Potassium chloride dissociates to potassium ions, which are essential for maintaining intracellular osmolarity, transmembrane electrochemical gradients, and normal neuromuscular excitability. Dextrose 5% provides a source of calories and may help shift potassium intracellularly via insulin secretion.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys (90%) with minor fecal loss; dextrose is metabolized via glycolysis and oxidation to carbon dioxide and water. |
| Excretion | Renal: >90% of potassium is excreted by the kidneys, primarily via distal tubular secretion; fecal and sweat losses account for <10%. |
| Half-life | Not applicable; potassium is not eliminated by first-order kinetics; distribution half-life is approximately 1 hour, with terminal elimination dependent on renal function. |
| Protein binding | Minimal; potassium is not significantly protein-bound (<1%). |
| Volume of Distribution | Approximately 0.15–0.3 L/kg for total body potassium; extracellular volume is about 0.05 L/kg. |
| Bioavailability | IV: 100%; oral: ~90% (not applicable for this parenteral formulation). |
| Onset of Action | IV: Immediate upon infusion; correction of hypokalemia begins within minutes, with full electrolyte equilibration occurring within several hours. |
| Duration of Action | Duration is variable depending on dose and renal function; potassium levels may remain elevated for 2–6 hours post-infusion, with sustained effects as long as infusion continues. |
| Molecular Weight | 74.55 |
40 mEq intravenously over 2-4 hours, not to exceed 10 mEq/hour or 200 mEq/day; requires continuous ECG monitoring.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25%; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: avoid use or reduce by 75% with monitoring. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: avoid use or reduce by 50% with monitoring. |
| Pediatric use | 0.5-1 mEq/kg/dose intravenously over 2-4 hours, not to exceed 1 mEq/kg/hr or 40 mEq/dose; requires ECG monitoring. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 20 mEq over 4 hours); monitor renal function and serum potassium levels more frequently; avoid in patients with decreased renal function or drugs that increase potassium. |
| 1st trimester | Potassium chloride is generally considered safe in pregnancy when used to correct hypokalemia. No increased risk of congenital anomalies has been reported. Use only if clearly needed. |
| 2nd trimester | Same as t1. Potassium chloride can be used if clinically indicated. Monitor serum potassium levels. |
| 3rd trimester | Use with caution near term as hyperkalemia may cause maternal complications. Avoid if renal impairment or preeclampsia. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta by active transport, maintaining fetal serum levels slightly lower than maternal. No evidence of harm at therapeutic doses. |
| Breastfeeding | Potassium chloride is naturally present in breast milk. Exogenous potassium does not significantly alter milk levels. Use caution only if maternal hyperkalemia is present. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride is a normal physiological constituent; no teratogenic effects are expected at therapeutic doses. However, maternal hyperkalemia may cause fetal arrhythmias or acidosis. First trimester: No known structural teratogenicity. Second/Third trimester: Fetal risk is secondary to maternal electrolyte imbalance; maternal hyperkalemia >5.5 mEq/L may impair placental perfusion and cause fetal bradycardia. |
| Fetal Monitoring | Monitor maternal serum potassium, glucose, and ECG during infusion. Fetal heart rate monitoring may be warranted if maternal hyperkalemia (potassium >5.0 mEq/L) or cardiac arrhythmias develop. Assess for signs of fluid overload (dextrose component). |
| Fertility Effects | No adverse effects on fertility are expected from potassium or dextrose at therapeutic doses. Potassium is essential for normal cellular function; deficiency or excess may disrupt reproductive hormone balance, but no direct impairment of fertility has been documented. |
■ FDA Black Box Warning
Concentrated potassium chloride (e.g., >40 mEq per dose) must be diluted and administered via an infusion pump. Undiluted or rapid infusion can cause fatal cardiac arrhythmias.
| Serious Effects |
Severe hyperkalemiaRenal failure with oliguria or anuriaSevere metabolic acidosisAddison's diseaseConditions involving concomitant potassium-sparing diuretics
| Precautions | Hyperkalemia risk, especially in patients with renal impairment, adrenal insufficiency, or concurrent use of potassium-sparing diuretics or ACE inhibitors, Use caution with metabolic acidosis and chronic renal disease, Monitor serum potassium, ECG, and clinical status during infusion, Extravasation risk; avoid undiluted infusion |
| Food/Dietary | Avoid high-potassium foods: bananas, oranges, orange juice, tomatoes, potatoes, spinach, avocados, dried fruits, nuts, beans, and salt substitutes (potassium chloride). Limit intake to prevent hyperkalemia. |
| Clinical Pearls | Potassium chloride in dextrose 5% is a hypertonic solution; infuse via central line to avoid phlebitis. Maximum infusion rate is 10 mEq/hour or 20 mEq/hour in critical care. ECG monitoring required for rates >10 mEq/hour. Contraindicated in severe renal impairment (GFR <30 mL/min), hyperkalemia, and complete heart block. Correct hypomagnesemia before potassium repletion to prevent refractory hypokalemia. |
| Patient Advice | Report any signs of hyperkalemia: muscle weakness, palpitations, paresthesias. · Do not consume potassium supplements or salt substitutes without doctor approval. · Avoid high-potassium foods like bananas, oranges, spinach, and potatoes. · Inform healthcare provider if you have kidney problems or are on ACE inhibitors, ARBs, or spironolactone. · This medication is given intravenously; report burning, pain, or redness at the IV site. |
Loading safety data…